Current News
“The CREA participates in an investigation to evaluate a new Alzheimer’s screening method.”
We are pleased to announce our participation in an innovative project featured in CREA. Below is the text of the publication:
Biocross has initiated a study to evaluate the quantification of Apolipoprotein E4 (ApoE4) as a risk marker for Alzheimer's disease, cardiovascular diseases, and type II diabetes mellitus.
In this project, which involves collaboration between various Spanish and Mexican institutions, Biocross has provided the Imserso reference center with a turbidity analyzer laboratory equipment for the study's development.
This research opens up the...
Pablo Cabello: “Reducing ApoE4 in Carriers is a Therapeutic Goal in Alzheimer’s Disease”
Dr. Pablo Cabello Albendea, from the Hospital Ramón y Cajal, emphasizes the importance of reducing the levels of the APOE4 protein in carriers to treat Alzheimer's disease. A recent study by the “National Institute of Aging” suggests that reducing APOE4 can be therapeutic and that it is crucial to identify and quantify this protein to personalize treatments. Additionally, new gene therapies and strategies combined with anti-amyloid treatments are being explored. Research needs to address when and how to apply...
Biocross: “A Simple Test Can Identify the Risk or Prognosis of Developing Alzheimer’s in the Futur
The company Biocross has developed two innovative blood tests, e4Risk® and e4Quant®, which identify and quantify the presence of the APOE4 gene, related to various metabolic and neurodegenerative diseases such as type 2 diabetes, cardiovascular diseases, and Alzheimer’s. A recent study by the Research Institute of the Hospital de la Santa Creu i Sant Pau in Barcelona revealed that almost all individuals with a duplication of the APOE4 gene develop biomarkers associated with dementia. These tests represent a significant...
Apoe4: A new genetic cause of Alzheimer’s discovered that affects more than 2% of the population
The Research Institute of the Hospital de la Santa Creu i Sant Pau in Barcelona has identified a new genetic form of Alzheimer's: the duplication of the APOE4 gene. This discovery highlights the importance of the APOE4 gene in Alzheimer's research.
Biocross aims to position APOE4 as a reference biomarker for the risk/prognosis of diseases related to alterations in lipid metabolism (Alzeimer's, cardiovascular diseases, Diabetes Mellitus Type II, pathologies that grow above the population average) and to identify and quantify...
Summary Video of the Event: “Cerco al Alzheimer”
The "Cerco al Alzheimer" event, held on September 14, 2023, at the European University of Alcobendas, brought together some of the leading specialists in the field of dementia to discuss the current state of research, new therapies, and diagnostic methods in an open format.
One of the key topics discussed mainly during the first two panels of the day was the importance of assessing the risk of both rapid disease progression and the occurrence of serious side effects with new...
